Roivant Sciences Ltd.
ROIV Healthcare Biotechnology
In the quarter to June 2026, revenue fell 33.6%, EPS grew 21.2% and free cash flow fell 30.0%, each against the same quarter a year earlier.
Follow ROIV
Roivant Sciences Ltd. (ROIV) EV/Sales
As of 16 October 2026, Roivant Sciences Ltd. (ROIV) trades at a EV/Sales of 2,742×. Over the past ten years it has ranged from 0.0× (March 2021) to 3,534× (September 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1,846× | 1,846.46% |
| FY2025 | 94.9× | 46.59% |
| FY2024 | 64.7× | (0.86%) |
| FY2023 | 65.3× | 147.43% |
| FY2022 | 26.4× | (85.05%) |
| FY2021 | 176× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2,920× | 58.11% |
| Mar 2026 | 1,846× | 125.15% |
| Dec 2025 | 820× | 167.15% |
| Sep 2025 | 307× | 104.51% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| EXEL Exelixis, Inc. compare | 6.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| INSM Insmed, Inc. compare | 18.1× |
| ROIV Roivant Sciences Ltd. | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)